TABLE 3.
Clinical characteristics of SARS‐CoV‐2‐positive patients
| N (98) | % | |
|---|---|---|
| Rationale for initial testing | ||
| Asymptomatic | 32 | 32.7 |
| Initially asymptomatic, who developed symptoms | 7 | 7.1 |
| Symptomatic | 66 | 67.3 |
| Symptoms | 73 | 100 |
| Fever | 60 | 82.2 |
| Cough | 45 | 61.6 |
| Respiratory distress | 19 | 26.0 |
| Vomiting or diarrhea | 8 | 11.0 |
| Anosmia | 4 | 5.5 |
| Ageusia | 3 | 4.1 |
| Myalgias | 11 | 15.1 |
| Fatigue | 18 | 24.7 |
| Sore throat | 5 | 6.8 |
| Other* | 17 | 23.3 |
| COVID‐19 disease severity (DSS) | 98 | 100 |
| Asymptomatic | 25 | 25.5 |
| Mild | 45 | 45.9 |
| Moderate | 11 | 11.2 |
| Severe | 17 | 17.3 |
| Respiratory support | 98 | 100 |
| Supplemental oxygen | 25 | 25.5% |
| Mechanical ventilation | 7 | 7.1% |
| Complications attributable to COVID‐19 | 98 | 100 |
| Bacterial superinfection | 7 | 7.1% |
| Acute respiratory distress syndrome | 12 | 12.2% |
| Acute kidney injury | 4 | 4.1% |
| Other ± | 9 | 9.2% |
| COVID‐19‐directed treatments | 98 | 100 |
| Hydroxychloroquine | 15 | 15.3 |
| Azithromycin | 15 | 15.3 |
| Tocilizumab | 5 | 5.1 |
| Remdesivir | 4 | 4.1 |
| Other | 7 | 7.1 |
| Anakinra, prednisolone | 1 | 2.0 |
| Convalescent plasma | 2 | 2.0 |
| Additional therapies | 98 | 100 |
| Hematopoietic growth factors | 18 | 18.4 |
| Anticoagulation therapies | 19 | 19.4 |
| Prophylactic dosing | 13 | 13.3 |
| Therapeutic dosing, no VTE | 3 | 3.1 |
| Therapeutic dosing, + VTE | 3 | 3.1 |
| Death # | 4 | 4.1% |
Clinical characteristics of pediatric oncology patients undergoing active anti‐cancer therapy with SARS‐CoV‐2 positivity by nasopharyngeal swab PCR are outlined above.
*Other COVID‐19 symptoms included (N) increased supplemental O2 support from baseline (2), congestion (4), headache (5), rhinorrhea (3), irritability (1) and anorexia (1).
±Other complications of COVID‐19 included fungemia, aspiration pneumonia, seizures, thromboembolism and one case of suspected “hyperinflammatory syndrome” (as reported by one institution).
#No death was solely attributed to COVID‐19.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.